Pain Tx in the News
Pain Tx in the News
Potentially harmful pain relief supplement is being sold under new name . . . Crush-resistant Opana ER is available in 2 new strengths . . . FDA approves Zecuity, a sumatriptan patch for migraine treatment
January 22, 2013
Latest news in the treatment of chronic pain.
Potentially harmful pain relief supplement is being sold under new name
The US Food and Drug Administration (FDA) has issued a
that a potentially harmful dietary supplement, Reumofan Plus, is being relabeled and sold under the name “Wow.” The supplement is marketed for the treatment of arthritis, muscle pain, osteoporosis, bone cancer, and other conditions.
According to an FDA laboratory analysis, Wow contains the same undeclared prescription drug ingredients found in Reumofan Plus: dexamethasone, diclofenac sodium, and methocarbamol. These ingredients may interact with other medications and cause serious adverse events.
In June and August 2012, the FDA warned the public about potential harm from using Reumofan Plus after receiving dozens of adverse event reports from consumers. The reports included liver injury, severe bleeding, corticosteroid withdrawal syndrome, adrenal suppression, stroke, and death.
Since the FDA’s warning, some distributors have relabeled Reumofan Plus as Wow to sell remaining supplies to online retailers, other distributors, and directly to consumers. Manufactured by Riger Naturals S.A., Reumofan Plus and Wow products are sold on various Web sites.
Health care providers should ask patients whether they use Reumofan Plus, Wow, or similar dietary supplements if they present with unexplained symptoms that suggest:
nonsteroidal anti-inflammatory drug (NSAID) toxicity
use or abrupt discontinuation of corticosteroids.
The FDA is asking health care professionals to report any adverse events related to the use of these products to the
MedWatch Safety Information and Adverse Event Reporting Program
Crush-resistant Opana ER is available in 2 new strengths
Last month, Endo Health Solutions introduced a 7.5- and 15-mg strength tablet to its line of crush-resistant Opana ER (oxymorphone HCl extended-release) tablets. The 2 new strengths join existing crush-resistant offerings that include 5-, 10-, 20-, 30-, and 40-mg tablets.
An opioid agonist, Opana ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period. Endo reports that surveillance data suggest that the introduction of the crush-resistant formulation of Opana ER beginning in February 2012 has led to reduced abuse rates of the drug when compared to the non-crush resistant version the company discontinued in May.
For the prescribing information, including important safety information, go to:
For information on the Food and Drug Administration’s new draft guidance on abuse deterrent opioid formulations, see “
FDA proposal encourages development of abuse deterrent opioids
FDA approves Zecuity, a sumatriptan patch for migraine treatment
on January 17, 2013, that the Food and Drug Adminstration (FDA) has approved Zecuity (sumatriptan iontophoretic transdermal system), a battery-powered skin patch, for the acute treatment of migraine with or without aura in adults. The single-use patch is the first migraine patch approved by the FDA.
The device uses a low electrical current to deliver 6.5 mg of sumatriptan over 4 hours through the skin; patients apply the patch to their upper arm or thigh. If headache relief is incomplete, a second patch can be applied to a different site. No more than 2 patches, however, should be used in a 24-hour period.
In phase 3 trials, Zecuity was proven safe and effective in treating migraine and relieving such symptoms as headache pain, migraine-related nausea, and sensitivity to light and sound 2 hours after patch activation. The most common adverse reactions reported by study patients included application site pain, paresthesia, itching, warmth, and discomfort.
Individuals who have cardiac disease, stroke, peripheral vascular disease, severe liver disease, and other serious conditions should not use the sumatriptan patch.
Physicians should review the drug’s
full prescribing information
for contraindications and warnings and precautions before prescribing Zecuity. Note that the patches contain metal parts and must be removed before patients undergo magnetic resonance imaging procedures to avoid risk of injury.
The manufacturer anticipates that the migraine patch will be available for clinical use in the fourth quarter of 2013.
New labeling approved for OxyContin . . . 32-Contact-point spinal cord stimulator launched . . . Implantable buprenorphine NDA nixed
Guidance on opioid prescribing … Evidence on alternative therapies for IBS … Benefits of vitamin D for chronic pain
IBS class helps patients manage symptoms … FDA issues call to action against opioid epidemic … Program with CBT and exercise benefits seniors in pain
Ambulatory infusion system gets FDA clearance . . . New therapeutic option proves helpful for treatment-refractory RA . . . Implantable buprenorphine gets priority review
Hydrocodone/acetaminophen tablets recalled . . . Analgesic use linked to hearing loss in women
FDA approves Xeljanz for RA ... Cochrane review affirms efficacy of topical NSAIDs for musculoskeletal pain
Most Viewed Topics
Chronic pain/Central pain
Most Viewed Articles
Most Searched Terms
Frontline Medical Communications
, Parsippany, NJ, USA.
All rights reserved
. Unauthorized use prohibited.
The information provided on chronicpainperspectives.com is for educational purposes only. Use of this Web site is subject to the